Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 55,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亚州雷德伍德城，2024年11月20日（GLOBE NEWSWIRE）——Adverum Biotechnologies, Inc.（纳斯达克股票代码：ADVM）今天宣布，根据Adverum的2017年激励计划，Adverum董事会薪酬委员会向新员工发放了一项由不合格股票期权组成的激励性奖励，用于向新员工购买55,000股普通股。根据纳斯达克上市规则5635（c）（4），Adverum董事会薪酬委员会批准该奖励作为新员工就业的激励材料。
The stock option has an exercise price per share equal to $6.86, Adverum's closing trading price on November 15, 2024, and will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and 1/48th of the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Adverum through the applicable vesting dates. The award is subject to the terms and conditions of Adverum's 2017 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
股票期权的每股行使价等于6.86美元，即Adverum在2024年11月15日的收盘交易价格，将在四年内归属，25％的标的股票在适用的归属开始日一周年之际归属，标的股份余额的1/48将在36个月内每月归属，但要视新员工在适用的归属日期之前与Adverum的持续服务关系而定。该奖励受Adverum2017年激励计划的条款和条件以及涵盖该补助金的适用奖励协议的条款和条件的约束。
About Adverum Biotechnologies
关于 Adverum 生物技术
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .
Adverum Biotechnologies（纳斯达克股票代码：ADVM）是一家处于临床阶段的公司，旨在将基因疗法确立为高度流行的眼部疾病的新护理标准，以开发恢复视力和预防失明的功能性疗法。利用其专有的玻璃体内注射（IVT）平台的功能，Adverum正在开发耐用的单一给药疗法，该疗法旨在在医生办公室交付，从而无需频繁进行眼部注射来治疗这些疾病。Adverum正在评估其新的候选基因疗法ixoberogene soroparvovec（ixo-vec，前身为advm-022），这是一种针对新生血管或湿性年龄相关性黄斑变性患者的一次性体外静脉注射剂。此外，通过克服与当前使人衰弱的眼部疾病治疗模式相关的挑战，Adverum渴望改变护理标准，保持视力，并在全球范围内产生深远的社会影响。欲了解更多信息，请访问。
Inquiries:
查询：
Adverum Investor Relations
Adverum 投资者关系
Email: ir@adverum.com
电子邮件：ir@adverum.com
